Anomaly Bio

Based in Singapore, Anomaly Bio Pte. Ltd. dba Anomaly Bio specializes in developing functional ingredients using advanced fermentation processes, transforming simple sugars into essential components for industries like nutrition, agriculture, and personal care. Anomaly Bio, founded in 2025, is headquartered in San Francisco, US.

The company focuses on innovative biomanufacturing techniques through engineered microbes. In November 2025, Anomaly Bio raised USD 2. 6 mn in pre-seed funding led by Pebblebed, marking its first significant investment round. The founder's background is not specified, and there are no known subsidiaries or parent companies.

Anomaly specializes in the development of functional ingredients through advanced fermentation processes, transforming simple sugars into essential components for various industries including nutrition, crop protection, and personal care. Their core technology centers on engineered microbes that function as micro-factories, allowing for scalable, on-demand production of these ingredients. Anomaly's offerings aim to address the demand for resilient ingredient supply chains, minimizing reliance on fragile biological and environmental constraints. Primarily serving North America and Europe, the company targets diverse clients, including health and wellness manufacturers, agricultural firms, and personal care product developers.

Anomaly's revenue model is structured around B2B partnerships, providing functional ingredients to industry players. The company conducts direct transactions with clients requiring reliable ingredient supplies for their products. Revenue is derived from engineered microbial solutions sold under potential contract agreements, with pricing based on volume or specific client needs. While specific pricing plans are not disclosed, the model likely accommodates bulk purchases to incentivize larger transactions, catering to various applications to meet market demands.

In November 2025, Anomaly Bio raised USD 2. 6 mn in pre-seed funding, led by Pebblebed, to support the development of its laboratory and pilot-scale facilities. The company plans to design and launch new products while expanding into additional markets in North America and Europe. Future initiatives will focus on enhancing its biomanufacturing capabilities to meet growing market demands.